{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.299","value":"171.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"}],"units":"Participants"}],"title":"C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.331","value":"294.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"}],"units":"Participants"}],"title":"C4D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"}],"units":"Participants"}],"description":"CEOI+1 hour was defined as the plasma concentration of isatuximab at 1 hour after end of infusion.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG000","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Analysis was performed on PK population. Here, 'Number analyzed' = participants with available data for each specified category. Data for this OM was not planned to be collected and analyzed for Pd arm.","reportingStatus":"POSTED","timeFrame":"Cycle 1:1 hour after End of Infusion on Day 1; Cycle 4:1 hour after End of Infusion on Day 1","title":"Pharmacokinetic Parameter: Plasma Concentration of Isatuximab at 1 Hour After End of Infusion (CEOI+1 Hour)","type":"SECONDARY","unitOfMeasure":"mcg/mL"}